skip to Main Content
Get your free newsletter: Actionable insight each morning for self-directed investors. 

I am not sure anyone expected Friday’s volatility shock – the fact the VIX index exploded 10 points (54%) to 28%, crude fell 13% and long volatility strategies lit-up portrays the one-sided skew in positioning – many will claim they expected a move lower in risk and that is fair, but these were huge moves.

Across asset class we saw some of the biggest percentage changes since the pandemic breakout – case in point, the 4.7% close lower in the EU Stoxx 50 index was a 6.4 Z-score move.

Friday was also a classic flow move, where the overriding feeling was that market players went into capital preservation mode and adopted a mindset of a return of one’s equity – Funds de-risked and de-grossed as volatility rose, and over-levered positions caused forced selling – gamma related flows in options land kicked in and again this just exasperated the movement.

One naturally questions if size sellers were met with a lower top of book liquidity, that exasperated price moves – That changes today as trading desks are fully manned through EU and US trade.

Headlines to dominate

Headlines will now dominate and drive price action above all other considerations, and while we have some tier 1 data to focus on this week, such as US non-farm payrolls, we all become scientists again. Choosing which headlines are noise and which ones are genuinely going to move sentiment is where money will be made, and that is difficult as emotion can often take over. As always, price is the final arbiter and that will be guided by semantics.

One even questions if data matters that much anyhow – I guess the market will make up its collective mind sooner than later on whether protections offered by current vaccines are effective and we can (hopefully) move back to obsessing over inflation and how many rate hikes are priced in 2022 and beyond. Until we feel assured that Omicron is not going to alter the way we live too intently in high vaccination countries then markets may be less sensitive to the economic data points.

We wait for real colour on the efficacy of current vaccinations against severe cases…hospitalization and fatalities. If the new variant undermines what we have been vaccinated against then what we’ve seen in markets on Friday is probably not an overreaction. We may not truly know the answers to that for a period of time

For those who however are keen to get amongst the headlines, having a keen eye on movements in Gauteng province in SA seems logical, which is where ground zero seems to be for Omicron. We have seen just how transmissible the virus is, with cases coming to light in a number of countries, resulting in a rapid closing of borders, while some have added fresh restrictions.

Watch guidance from big pharma

Having an eye on Moderna and Pfizer seems logical too – a 21% rally for Moderna on Friday shows the market sees pharma (along with Pfizer) having a big role in shaping our understanding and affecting broad sentiment across markets. Tests on whether the current dose of Spikevax has the desired effects on Omicron or whether more needs to be done could be a very useful guide for market participants.

What will cause central banks to pivot?

In a world where central banks are in the process of normalising policy, it leads to a more challenging situation and one where markets will search out what It will take to see them pivot and move to a more dovish stance – the barriers, I suspect, are high and that could lead to a solid correction in risk as market test out central banks – again that will be dictated by whether the market sees the worst-case scenario as a real threat.

Crude is a must watch

Crude is a must-watch this week – not only has price closed below its 200-day MA for the first time since November 2020 but has moved c.20% since 10 November. This makes Thursday’s OPEC meeting even more interesting. It feels like a halt to its planned output increase is a given, but will there be talk of output cuts? I feel this is a low probability but given crude 13% decline on Friday, I feel SpotCrude and Brentcrude could see real interest this week from traders.

Will any rallies be a one-day affair? This is a fickle market, and the risks to me are that until we have clarity there are two-way risks in markets and volatility should remain elevated – a trader’s market.

This article is brought to you in association with Pepperstone. All opinions expressed in this article are from the author and do not necessarily represent the opinions of The Armchair Trader.

Please note this article does not constitute investment advice. Investors are encouraged to do their own research beforehand or consult a professional advisor.

Chris Weston

Chris Weston

Chris Weston is Pepperstone’s Head of Research and holds over 20 years of experience trading and analysing markets. A highly-respected markets expert, Chris has worked at IG, Merrill Lynch, Credit Suisse and Morgan Stanley, covering research as well as sales and trading roles. His extensive exposure to the FX, equities and fixed income markets puts him in a unique position to provide inspiring insights, research, ideas and risk-management strategies that support every step of your trading journey. Based in Australia, Chris is a well-known global media figure, regularly appearing on Bloomberg, CNBC, Channel News Asia and Sky News

Stocks in Focus

Here are some of the smaller companies we are following most closely. They all represent significant growth stories in our view. Our in-depth reports go into more detail on why we like them.

Comments

Subscribe for more stories like this, 8am weekdays - for free!


Get your free daily newsletter: 

Thanks to our Partners

Our partners are established, regulated businesses and we are grateful for their support.

Pepperstone
FP Markets
IG
Spreadex
WisdomTree
ActivTrades
Back To Top